. 2022 Jul 30;10(8):1841. doi: 10.3390/biomedicines10081841

Table 1.

Surface Antigen Phenotypes of AML and CML LSCs.

Malignancy	Surface Antigen Phenotype	Significance	References
AML	CD34⁺CD38⁻	Denotes a primitive subpopulation of stem/progenitor cells in AML	[6]
	CD33⁺	Selectively overexpressed in AML patients compared to healthy HSCs	[21]
	CD123⁺	Selectively overexpressed on AML cells and potentially facilitates STAT5 activation	[22,23,24,25]
	CD47⁺	Assists AML LSCs with apoptotic evasion via phagocytic inhibition of circulating macrophages and dendritic cells	[26,27,28]
	CD96⁺	Upregulated in AML cells and enriches LSC activity	[29]
	CD99⁺	Selectively overexpressed on AML LSCs, particularly at disease relapse	[30]
	CD45^dimCD34⁺CD38⁻CD133⁺	Enriched in AML BM samples and associated with poor overall and event-free survival of AML patients	[31]
CML	CD34⁺CD38⁻	Denotes a primitive subpopulation of stem/progenitor cells in CML	[36,38]
	CD33⁺	Chronic phase CML patients exhibit a roughly 10-fold higher expression of CD33 compared to CD34⁺CD38⁻ cells from healthy individuals	[42]
	IL1RAP	Upregulated in CD34⁺ and CD34⁺CD38⁻ CML cells. Further upregulated in accelerated and blast crisis phases compared to chronic phase	[43]
	CD34⁺CD38⁻CD26⁺	Exhibits repopulating capacity in NSG mice and upregulated in imatinib-nonresponders	[44,45]
	Lin-CD34⁺CD38^−/lowCD45RA⁻cKIT⁻CD26⁺	Denotes CML LSCs that are particularly insensitive to TKI therapies	[46]